186 related articles for article (PubMed ID: 17332623)
1. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
[TBL] [Abstract][Full Text] [Related]
3. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
Akiyama H; Mohamedali KA; E Silva RL; Kachi S; Shen J; Hatara C; Umeda N; Hackett SF; Aslam S; Krause M; Lai H; Rosenblum MG; Campochiaro PA
Mol Pharmacol; 2005 Dec; 68(6):1543-50. PubMed ID: 16150930
[TBL] [Abstract][Full Text] [Related]
4. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
Veenendaal LM; Jin H; Ran S; Cheung L; Navone N; Marks JW; Waltenberger J; Thorpe P; Rosenblum MG
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):7866-71. PubMed ID: 12060733
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli.
Kim S; Mohamedali KA; Cheung LH; Rosenblum MG
J Biotechnol; 2007 Feb; 128(3):638-47. PubMed ID: 17218033
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
[TBL] [Abstract][Full Text] [Related]
8. A vascular endothelial growth factor 121 (VEGF(121))-based dual PET/optical probe for in vivo imaging of VEGF receptor expression.
Kang CM; Koo HJ; Lee KC; Choe YS; Choi JY; Lee KH; Kim BT
Biomaterials; 2013 Sep; 34(28):6839-45. PubMed ID: 23787114
[TBL] [Abstract][Full Text] [Related]
9. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts.
Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K
Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
12. PET of vascular endothelial growth factor receptor expression.
Cai W; Chen K; Mohamedali KA; Cao Q; Gambhir SS; Rosenblum MG; Chen X
J Nucl Med; 2006 Dec; 47(12):2048-56. PubMed ID: 17138749
[TBL] [Abstract][Full Text] [Related]
13. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
Tirand L; Frochot C; Vanderesse R; Thomas N; Trinquet E; Pinel S; Viriot ML; Guillemin F; Barberi-Heyob M
J Control Release; 2006 Mar; 111(1-2):153-64. PubMed ID: 16423422
[TBL] [Abstract][Full Text] [Related]
14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
16. Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis.
Cao Q; Cai W; Niu G; He L; Chen X
Clin Cancer Res; 2008 Oct; 14(19):6137-45. PubMed ID: 18829492
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.
Mohamedali KA; Ran S; Gomez-Manzano C; Ramdas L; Xu J; Kim S; Cheung LH; Hittelman WN; Zhang W; Waltenberger J; Thorpe PE; Rosenblum MG
BMC Cancer; 2011 Aug; 11():358. PubMed ID: 21849059
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
